By analysis of CD4+CD25+Foxp3+ cells in the tumor tissues, we found that the combined therapies (E7 + RT and RT + E7) did not change the intratumoral percentage of Tregs (Fig. 4a), indicating that E7 + RT therapy could induce a higher ratio of CD8+ T cells/Tregs in the tumors that contributes to its better antitumor effect. This evidence concerns the gene CD8A and neoplasm.